Doctors Reveal The Most Common Side Effects Of GLP-1s — And How To Manage ThemDoctors Reveal The Most Common Side Effects Of GLP-1s — And How To Manage Them
Ozempic, Wegovy and other GLP-1 medications are popular but can cause unwanted health concerns. Ozempic, Wegovy and other GLP-1 medications are popular but can cause unwanted health concerns.
Wegovy Now Approved for Treatment of Severe Liver DiseaseWegovy Now Approved for Treatment of Severe Liver Disease
The US Food and Drug Administration (FDA) has approved an injectable semaglutide treatment for adults with a form of fatty liver disease called metabolic dysfunction–associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis but not cirrhosis. According to an FDA press release announcing the decision, MASH affects 6% of US adults and can lead Read More
1 in 4 US Adults With Diabetes Used Injectable GLP-1 Drugs Last Year1 in 4 US Adults With Diabetes Used Injectable GLP-1 Drugs Last Year
Between 2016 and 2022, the rate of US adults with type 2 diabetes who used glucagon-like peptide-1 (GLP-1) receptor agonists rose from about 4% to nearly 20%, according to the Medical Expenditure Panel Survey Household Component. Now, new data from the Centers for Disease Control and Prevention reveal that almost 27% of adults diagnosed with Read More
FDA Says Yes to Cryoablation for Early Breast CancerFDA Says Yes to Cryoablation for Early Breast Cancer
(MedPage Today) — The FDA granted marketing authorization for the ProSense Cryoablation System for small, early-stage breast cancer in older women not suitable for surgery, maker IceCure announced.
A minimally invasive tool that destroys tumors…
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder DrugsCostco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs
Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website. Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.
This new semaglutide dose helped nearly half of patients lose 20% body weightThis new semaglutide dose helped nearly half of patients lose 20% body weight
The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment Read More
This new semaglutide dose helped nearly half of patients lose 20% body weightThis new semaglutide dose helped nearly half of patients lose 20% body weight
The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, while also improving metabolic health. Side effects were mostly mild and temporary. Researchers say this could reshape obesity treatment […]
Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad SayPick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say
(MedPage Today) — A new treatment algorithm from the European Association for the Study of Obesity (EASO) recommends opting for semaglutide (Wegovy) or tirzepatide (Zepbound) first when “substantial” weight loss is needed in a patient. The two… (MedPage Today) — A new treatment algorithm from the European Association for the Study of Obesity (EASO) Read More
Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidanceSemaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) published in the journal Nature Medicine. Semaglutide or tirzepatide should be the Read More
GLP-1 Receptor Agonists and Cancer Risk in Adults With ObesityGLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity. This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity.